Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02422329
Other study ID # 2015-0111
Secondary ID NCI-2015-00734
Status Completed
Phase N/A
First received April 16, 2015
Last updated March 20, 2018
Start date April 30, 2015
Est. completion date March 7, 2018

Study information

Verified date March 2018
Source M.D. Anderson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this research study is to learn how patients' think about constipation before and after receiving education about the subject.


Description:

If participant agrees to take part in the study, information about them (such as their age, gender, ethnicity, religion, diagnosis, and drugs they are currently taking) will be collected from their medical record.

Participant will also complete 1 questionnaire about constipation. It should take about 1-3 minutes to complete the questionnaire.

After completing the questionnaire, participant will be randomly assigned (as in the flip of a coin) to 1 of 2 study groups. This is done because no one knows if one study group is better, the same, or worse than the other group. Participant will have an equal chance of being in either group.

- If participant is assigned to Group 1, they will watch a short educational video.

- If participant is assigned to Group 2, they will read a fact sheet.

Both the video and the fact sheet describe symptoms of constipation and the importance of regular bowel movements. They should take about 3 minutes each to complete.

After participant has viewed the educational material, they will complete 3 questionnaires about constipation and how helpful they think the video or fact sheet was in educating them about constipation. It should take about 10 minutes total to complete these questionnaires. Participant will watch the video/read the fact sheet and complete the questionnaires in their room at the Supportive Care Clinic.

Length of Study:

Patient's participation on this study will be over after they have completed the last 3 questionnaires.

This is an investigational study.

Up to 200 participants will be enrolled in the study. All will take part at MD Anderson.


Recruitment information / eligibility

Status Completed
Enrollment 59
Est. completion date March 7, 2018
Est. primary completion date March 7, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Patients with diagnosis of advanced cancer, including recurrent, locally advanced, or metastatic cancer

2. Age >/= 18 years old

3. Patients must be able to understand, read, write, and speak English

4. Patients must have no clinical evidence of cognitive impairment as determined by the palliative care physician (Memorial Delirium Assessment Score >/= 7)

5. Patients must sign an informed consent

Exclusion Criteria:

1. Patients with a diagnosis of inflammatory bowel disease, i.e. Crohn's disease or ulcerative colitis

2. Patients with complete or partial bowel obstruction as determined by the palliative care physician

3. Patients with a bowel ostomy

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Questionnaires
Participants complete questionnaires at baseline and after intervention.
Video
Participants watch a 3-minute educational video describing symptoms of constipation and importance of regular bowel movements.
Fact Sheet
Participants read educational material describing symptoms of constipation and importance of regular bowel movements.

Locations

Country Name City State
United States University of Texas MD Anderson Cancer Center Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Patient-Reported Perception of Constipation Primary objective is to examine effect of educational intervention on the patient-reported perception of constipation (PRC, by a 0-10 numeric rating score) among advanced cancer patients. 1 day
See also
  Status Clinical Trial Phase
Completed NCT01213238 - Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab Phase 1
Recruiting NCT02160366 - Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patients
Completed NCT00903708 - LY2275796 in Advanced Cancer Phase 1
Completed NCT00379353 - The Effects of Thalidomide on Symptom Clusters Phase 2
Terminated NCT00499382 - Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging N/A
Completed NCT02459964 - Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain Phase 4
Completed NCT01430572 - Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients Phase 1
Completed NCT02561234 - A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT01375114 - The Effects of Ginseng on Cancer-Related Fatigue Phase 2
Completed NCT01454804 - Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors Phase 1
Completed NCT01201694 - Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L) Phase 1
Completed NCT02801045 - Art Therapy in Palliative Care: Study of Identification and Understanding of the Mechanisms of Change in the Patient N/A
Completed NCT02873975 - A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency Phase 2
Completed NCT01983969 - Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma Phase 1/Phase 2
Completed NCT02272595 - Rational Therapeutics Based on Matched Tumor and Normal Tissue
Active, not recruiting NCT01999491 - A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma Phase 1
Recruiting NCT03375983 - Plasmodium Immunotherapy for Advanced Cancers Phase 1/Phase 2
Completed NCT02571036 - A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies Phase 1
Withdrawn NCT01608139 - Study of Curcumin, Vorinostat, and Sorafenib Phase 1
Completed NCT01024166 - Patient-Reported Outcomes-Based Palliative and Hospice Care Practice: A Usability Study N/A